Madrigal Pharmaceuticals, Inc. (MDGL) — Financial statements
Income statement, balance sheet, and cash flow for Madrigal Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 958↑432.1% | 180 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 56↑800.8% | 6 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 902↑418.8% | 174 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 389↑64.1% | 237↓13.1% | 272↑11.0% | 245↑19.6% | 205 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 108↑124.7% | 48↑29.0% | 37 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 814↑87.1% | 435↑302.3% | 108↑124.7% | 48↑29.0% | 37 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 1,202↑79.0% | 672↑76.6% | 380↑29.6% | 294↑21.1% | 242 | |
| Total Costs & Expenses | 1,259↑85.6% | 678↑78.2% | 380↑29.6% | 294↑21.1% | 242 | |
| Operating Results | ||||||
| Operating Income | -300↑39.7% | -498↓30.8% | -380↓29.6% | -294↓21.1% | -242 | |
| Depreciation & Amortization | 2↑37.4% | 1↑108.0% | 0.53↑12.8% | 0.47↑15.3% | 0.41 | |
| EBITDA | -264↑41.2% | -450↓24.9% | -360↓23.9% | -291↓20.5% | -241 | |
| EBIT | -266↑41.1% | -451↓25.0% | -361↓23.9% | -291↓20.5% | -242 | |
| Interest & Other Income | ||||||
| Net Interest Income | 15↓52.9% | 32↑365.8% | 7↑485.9% | -2↓590.1% | 0.36 | |
| Interest Income | 37↓19.9% | 47↑138.3% | 20↑796.0% | 2↑501.9% | 0.36 | |
| Interest Expense | 22↑52.1% | 15↑15.4% | 13↑220.7% | 4 | 0.00 | |
| Non-Operating Income | -34↑26.9% | -47↓138.3% | -20↓796.0% | -2↓243.6% | -0.64 | |
| Other Income / Expenses | 12↓63.1% | 32↑365.8% | 7↑485.9% | -2↓379.7% | 0.64 | |
| Income Before Tax | -288↑38.1% | -466↓24.7% | -374↓26.5% | -295↓22.1% | -242 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -288↑38.1% | -466↓24.7% | -374↓26.5% | -295↓22.1% | -242 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -288↑38.1% | -466↓24.7% | -374↓26.5% | -295↓22.1% | -242 | |
| Bottom-Line Net Income | -288↑38.1% | -466↓24.7% | -374↓26.5% | -295↓22.1% | -242 | |
| EPS (Basic) | -12.85↑41.3% | -21.90↓9.6% | -19.99↓16.0% | -17.23↓17.8% | -14.63 | |
| EPS (Diluted) | -12.85↑41.3% | -21.90↓9.6% | -19.99↓16.0% | -17.23↓17.8% | -14.63 | |
| Weighted Average Shares | 22↑5.5% | 21↑13.8% | 19↑9.0% | 17↑3.6% | 17 | |
| Weighted Average Diluted Shares | 22↑5.5% | 21↑13.8% | 19↑9.0% | 17↑3.6% | 17 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.